Evidence map›Paper›PMID 26294421›Full record

ArticleBioscience reports2015

Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.

Ameena J Haider, Megan H Cox, Natalie Jones, Alice J Goode, Katherine S Bridge, Kelvin Wong, Deborah Briggs, Ian D Kerr

Abstract read
In one paragraph

Article in Bioscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. A NovelLife (Basel, Switzerland) · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2017
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ameena J HaiderSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Megan H CoxSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Natalie JonesSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Alice J GoodeSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Katherine S BridgeSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Kelvin WongSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Deborah BriggsSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K.
Ian D KerrSchool of Life Sciences, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, U.K. Ian.kerr@nottingham.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABCG2 is an ABC (ATP-binding cassette) transporter with a physiological role in urate transport in the kidney and is also implicated in multi-drug efflux from a number of organs in the body. The trafficking of the protein and the mechanism by which it recognizes and transports diverse drugs are important areas of research. In the current study, we have made a series of single amino acid mutations in ABCG2 on the basis of sequence analysis. Mutant isoforms were characterized for cell surface expression and function. One mutant (I573A) showed disrupted glycosylation and reduced trafficking kinetics. In contrast with many ABC transporter folding mutations which appear to be 'rescued' by chemical chaperones or low temperature incubation, the I573A mutation was not enriched at the cell surface by either treatment, with the majority of the protein being retained in the endoplasmic reticulum (ER). Two other mutations (P485A and M549A) showed distinct effects on transport of ABCG2 substrates reinforcing the role of TM helix 3 in drug recognition and transport and indicating the presence of intracellular coupling regions in ABCG2.

Indexed as

ATP-Binding Cassette TransportersDirected Molecular EvolutionMutation, MissenseNeoplasm ProteinsAmino Acid SubstitutionATP Binding Cassette Transporter, Subfamily G, Member 2HEK293 CellsHumansProtein TransportABCG2 protein, humanATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsATP-binding cassette (ABC) transporterdrug bindingglycosylationtraffickingtransmembrane helix

Identifiers

PMID26294421
PMCPMC4613716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.